Revolution Medicines, Inc. $RVMD Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP lowered its position in Revolution Medicines, Inc. (NASDAQ:RVMD) by 36.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,843,415 shares of the company’s stock after selling 2,184,404 shares during the quarter. Wellington Management Group LLP owned 1.79% of Revolution Medicines worth $719,795,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in RVMD. Beacon Pointe Advisors LLC acquired a new stake in Revolution Medicines in the 2nd quarter valued at about $346,000. Livforsakringsbolaget Skandia Omsesidigt purchased a new position in Revolution Medicines during the 2nd quarter valued at about $187,000. Empowered Funds LLC acquired a new position in Revolution Medicines during the second quarter worth about $9,755,000. United Capital Financial Advisors LLC acquired a new position in Revolution Medicines during the second quarter worth about $595,000. Finally, Equitable Holdings Inc. purchased a new stake in shares of Revolution Medicines in the second quarter valued at about $963,000. Institutional investors and hedge funds own 94.34% of the company’s stock.

Insider Activity at Revolution Medicines

In other news, CFO Jack Anders sold 20,000 shares of Revolution Medicines stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $168.33, for a total value of $3,366,600.00. Following the completion of the sale, the chief financial officer owned 123,269 shares of the company’s stock, valued at $20,749,870.77. The trade was a 13.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mark A. Goldsmith sold 80,000 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $209.20, for a total value of $16,736,000.00. Following the completion of the transaction, the insider owned 267,330 shares of the company’s stock, valued at $55,925,436. The trade was a 23.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 212,497 shares of company stock worth $38,206,486. Company insiders own 7.60% of the company’s stock.

More Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: FDA approval creates a major commercial opportunity. Rasonque became the first broad RAS-targeted therapy approved for metastatic pancreatic cancer and Revolution Medicines’ first marketed product. The approval arrived roughly five weeks after filing through the FDA’s national priority voucher program. In the pivotal RASolute 302 trial, the treatment reportedly nearly doubled survival outcomes, supporting expectations for rapid adoption. RVMD Secures FDA Win
• Positive Sentiment: Analysts raised their valuations. Guggenheim increased its price target to $275 from $240 with a Buy rating, while HC Wainwright maintained a Buy rating and a $280 target. Analysts cited potential peak sales of approximately $11.5 billion, and RBC viewed the planned launch as comparatively rapid. Revolution Medicines FDA Approval and Peak Sales
• Neutral Sentiment: Much of the good news may already be reflected in the stock. RVMD recently reached an all-time high above $224 and its market capitalization approached $47 billion. Commentary suggests investors had already priced in a successful approval, limiting additional upside from the announcement. Revolution Medicines Valuation Analysis
• Negative Sentiment: Profit-taking and risk concerns are weighing on shares. Despite the “transformative” approval, the stock is facing a weekly decline as investors lock in gains after a more-than-fivefold rally. Revolution Medicines remains unprofitable, with analysts forecasting negative EPS for 2027, although losses are expected to narrow to $6.86 per share for the full year. Revolution Medicines Shares Despite FDA Approval

Revolution Medicines Stock Performance

Shares of RVMD opened at $207.88 on Friday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 11.38 and a current ratio of 11.38. The company has a market capitalization of $44.56 billion, a price-to-earnings ratio of -23.57 and a beta of 1.39. The company’s 50 day simple moving average is $193.33 and its 200 day simple moving average is $148.59. Revolution Medicines, Inc. has a 1 year low of $37.56 and a 1 year high of $224.31.

Revolution Medicines (NASDAQ:RVMD) last announced its earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same period in the previous year, the business posted ($1.31) EPS. On average, sell-side analysts predict that Revolution Medicines, Inc. will post -8.85 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on RVMD shares. Sanford C. Bernstein increased their price target on shares of Revolution Medicines from $151.00 to $179.00 and gave the company a “market perform” rating in a research report on Friday, August 21st. Royal Bank Of Canada lifted their price objective on Revolution Medicines from $203.00 to $251.00 and gave the stock an “outperform” rating in a research report on Thursday. Wolfe Research reaffirmed an “outperform” rating and issued a $220.00 target price on shares of Revolution Medicines in a research note on Monday, August 10th. Raymond James Financial reiterated a “strong-buy” rating and set a $248.00 target price on shares of Revolution Medicines in a report on Thursday. Finally, Wedbush raised their price target on Revolution Medicines from $201.00 to $225.00 and gave the stock an “outperform” rating in a research report on Thursday. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Revolution Medicines has a consensus rating of “Moderate Buy” and an average target price of $198.89.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.